ArrowMark Colorado Holdings’s Royalty Pharma RPRX Stock Holding History

ArrowMark Colorado Holdings’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.5M	Sell	366,199 -554	-0.2%	-$28.8K	0.85%	21
2026 Q1	$17.6M	Sell	366,753 -745	-0.2%	-$32.6K	0.47%	64
2025 Q4	$14.2M	Sell	367,498 -12,908	-3%	-$492K	0.31%	92
2025 Q3	$13.4M	Sell	380,406 -9,042	-2%	-$327K	0.25%	105
2025 Q2	$14M	Hold	389,448	–	–	0.25%	106
2025 Q1	$12.1M	Hold	389,448	–	–	0.2%	111
2024 Q4	$9.93M	Buy	389,448 +317,698	+443%	+$8.42M	0.13%	138
2024 Q3	$2.03M	Buy	+71,750	New	+$1.99M	0.03%	229

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ArrowMark Colorado Holdings's RPRX Position: Q2 2026 in Review

ArrowMark Colorado Holdings reduced its Royalty Pharma (RPRX) stake by 0.15% in Q2 2026, selling an estimated $28.8K and leaving 366,199 shares worth $20.5M. The position accounts for 0.85% of the portfolio, ranked #21.

ArrowMark Colorado Holdings first reported a position in RPRX in Q3 2024 and has held it in 8 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

ArrowMark Colorado Holdings held 366,199 shares of Royalty Pharma worth $20.5M as of Q2 2026.
ArrowMark Colorado Holdings sold 554 Royalty Pharma shares in Q2 2026, an estimated $28.8K.
Royalty Pharma made up 0.85% of ArrowMark Colorado Holdings's portfolio in Q2 2026, its #21 holding.
ArrowMark Colorado Holdings first reported a position in Royalty Pharma in Q3 2024 and has held it in 8 quarters since.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.